Understand the source comparison
FOXO4-DRI for Biohackers: Research Peptide Comparison
FOXO4-DRI Disrupts FOXO4-p53 binding in senescent cells, releasing p53 to trigger apoptosis High (targets FOXO4-p53 complex unique to senescent cells) None. Preclinical rodent studies only Subcutaneous injection Lyophilized: −20°C; Reconstituted: 2–8°C, use wi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- FOXO4-DRI
- Disrupts FOXO4-p53 binding in senescent cells, releasing p53 to trigger apoptosis
- High (targets FOXO4-p53 complex unique to senescent cells)
- None. Preclinical rodent studies only
- Subcutaneous injection
- Lyophilized: −20°C; Reconstituted: 2–8°C, use within 7–10 days
- Most mechanistically selective senolytic candidate, but zero human trial data limits risk assessment
- Dasatinib + Quercetin (D+Q)
- Inhibits BCL-2 family proteins (dasatinib) and PI3K/AKT pathways (quercetin) to induce apoptosis
- Moderate (affects multiple cell types; senescent cells more vulnerable due to upregulated pro-survival pathways)
- Phase 1 completed (Mayo Clinic); Phase 2 ongoing for idiopathic pulmonary fibrosis
- Oral (dasatinib 100 mg + quercetin 1000 mg, 2 consecutive days/month)
- Room temperature (dasatinib stable as tablets)
- Best-studied senolytic protocol with emerging human safety data; broader target range than FOXO4-DRI
- Fisetin
- Inhibits PI3K, mTOR, and pro-survival kinases; induces autophagy in senescent cells
- Low to moderate (senolytic activity observed at high doses; lower doses act as antioxidant without clearing cells)
- Observational and small pilot studies (e.g., Mayo Clinic feasibility trial)
- Oral (1000–2000 mg/day for 2 consecutive days)
- Room temperature (stable as capsules)
- Natural flavonoid with senolytic activity at supraphysiological doses; weaker than D+Q or FOXO4-DRI but more accessible
- Navitoclax (ABT-263)
- BCL-2/BCL-xL inhibitor. Prevents senescent cells from resisting apoptosis
- High (potent senolytic; targets BCL-2 family overexpressed in senescent cells)
- Phase 2 trials for hematologic malignancies; not approved for senolytic use
- Oral (investigational. Not available for biohacking)
- Requires refrigeration (investigational compound)
- Most potent senolytic in preclinical studies, but severe thrombocytopenia limits use; not accessible outside clinical trials
- Spermidine
- Induces autophagy (cellular recycling) and mitophagy; reduces senescent cell accumulation indirectly
- Indirect (promotes cellular cleanup rather than inducing apoptosis)
- Multiple observational studies; associated with reduced cardiovascular mortality
- Oral (5–10 mg/day continuous dosing)
- Room temperature
- Well-tolerated longevity supplement; indirect senolytic effect through autophagy rather than targeted cell death